Infinity Pharmaceuticals Inc. To Host 2015 Research & Development Day

– Company to Provide an In-Depth Review of Duvelisib and IPI-549 Programs –

– Webcast to Begin at 8:00 A.M. ET –

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it will host a live webcast in conjunction with its 2015 Research & Development (R&D) Day for analysts and institutional investors on Tuesday, October 6, 2015, in New York City. At the meeting, Infinity plans to review the clinical development program for duvelisib and discuss the company’s newest development candidate, IPI-549. Additionally, presentations will be given by the following expert physicians:

• Jennifer R. Brown, M.D., Ph.D., director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School
• Steven M. Horwitz, M.D., associate attending for the Lymphoma Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center
• David A. Tuveson, M.D., Ph.D., Roy J. Zuckerberg professor of cancer research, director Cancer Therapeutics Initiative and deputy director of Cancer Center at Cold Spring Harbor Laboratory, director of research, the Lustgarten Foundation

The live webcast of Infinity’s R&D Day will be accessible on the “investors/media” section of the company’s website, www.infi.com, and a replay will be posted approximately one hour after the event and will be available for 90 days following the event.

About Infinity Pharmaceuticals, Inc.

Infinity is an innovative biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to people with difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. For more information on Infinity, please refer to the company’s website at www.infi.com.